Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

ABSTRACT:

Background

Linezolid has antimycobacterial activity in vitro and is increasingly used for patients with highly drug-resistant tuberculosis.

Methods

We enrolled 41 patients who had sputum-culture-positive extensively drug-resistant (XDR) tuberculosis and who had not had a response to any available chemotherapeutic option during the previous 6 months. Patients were randomly assigned to linezolid therapy that started immediately or after 2 months, at a dose of 600 mg per day, without a change in their background regimen. The primary end point was the time to sputum-culture conversion on solid medium, with data censored 4 months after study entry. After confirmed sputum-smear conversion or 4 months (whichever came first), patients underwent a second randomization to continued li

SUBMITTER: Lee M 

PROVIDER: S-EPMC3814175 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature